Associated TIE2 SNPs in nAMD and PCV adjusted for age and gender
| SNP | Nucleotide change | Risk allele | nAMD-Control | PCV-control | nAMD+PCV-control | |||
| Padjusted | Adjusted OR (95% CI) | Padjusted | Adjusted OR (95% CI) | Padjusted | Adjusted OR (95% CI) | |||
| Hong Kong Chinese | ||||||||
| rs625767 | c.53–22116C>T | C | 0.027 | 0.76 (0.60 to 0.97) | 0.078 | 0.81 (0.64–1.02) | 0.013 | 0.78 (0.65 to 0.95) |
| rs2273717 | c.3201-182A>G | A | 0.19 | 1.20 (0.91 to 1.59) | 0.029 | 1.37 (1.03–1.81) | 0.03 | 1.29 (1.03 to 1.62) |
| Shantou Chinese | ||||||||
| rs625767 | c.53–22116C>T | C | 0.54 | 0.93 (0.73 to 1.18) | 0.024 | 0.74 (0.58–0.96) | 0.075 | 0.83 (0.68 to 1.02) |
| rs2273717 | c.3201-182A>G | A | 0.28 | 0.85 (0.63 to 1.15) | 0.13 | 1.25 (0.94–1.66) | 0.72 | 1.04 (0.83 to 1.32) |
| Osaka Japanese | ||||||||
| rs625767 | c.53–22116C>T | C | 0.095 | 0.70 (0.46 to 1.06) | 0.66 | 1.09 (0.75–1.58) | 0.57 | 0.91 (0.64 to 1.28) |
| rs2273717 | c.3201-182A>G | A | 0.63 | 0.89 (0.56 to 1.42) | 0.54 | 0.87 (0.57–1.35) | 0.57 | 0.89 (0.59 to 1.33) |
nAMD, neovascular age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SNP, single-nucleotide polymorphism.